The US Food and Drug Administration (FDA) has granted priority review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle invasive bladder ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

Chemotherapy can increase mutation burden and change the cell population structure of normal blood, which contributes to long-term adverse effects such as second malignancies and infertility, ...

Thousands of workers at federal health agencies lost their jobs this week after a US Supreme Court ruling cleared the way for the Trump administration to move forward with major staffing cuts.

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Biomarker testing rates before first-line treatment increased over time, and rates of biomarker testing increased between first-line and second-line treatment.

The NIH is planning to limit how much publishers can charge NIH-supported scientists to make their research findings publicly available.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

Soon, many patients might initiate contact with the health system not by speaking with a call center worker or receptionist, ...

“djuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

Our study highlights a concerning 3-fold increase in obesity-related cancer deaths since 1999,” said study author Faizan Ahmed, MD.